Early Administration of Tocilizumab (Toci) for the Prevention of Grade 4 Cytokine Release Syndrome (CRS) after CD19-directed CAR T-cell Therapy (CTL019)
Kadauke, S., Maude, S., Gladney, W., Motley, L., Shenoy, V., Callahan, C., Baniewicz, D., Teachey, D.T., Grupp, S., DiNofia, A.Volume:
21
Language:
english
Journal:
Cytotherapy
DOI:
10.1016/j.jcyt.2019.04.009
Date:
May, 2019
File:
PDF, 532 KB
english, 2019